Drug intelligence / Profile preview

live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus

Development stage: Unknown
Lead developer: Takeda
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

This vaccine is a live, attenuated, recombinant formulation designed to protect against dengue fever caused by all four serotypes of the dengue virus (serotypes 1, 2, 3, and 4). It works by introducing weakened, genetically modified versions of the virus to stimulate the immune system to produce neutralizing antibodies, thereby conferring immunity.

Other names: Tetravalent Dengue Vaccine

Beyond the preview

Go deeper on live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus.

Explore the full profile